NEWEST CONTENT
-
REVIEW ARTICLESBertagnolli et al.March 25, 2020
-
CORRESPONDENCEGhadjar et al.March 25, 2020
-
CORRESPONDENCERoy et al.March 25, 2020
-
Original ReportsTap et al.March 24, 2020
-
CORRESPONDENCEGonzalez-Rodriguez et al.March 24, 2020
FEATURED CONTENT

RAPID COMMUNICATIONS
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Gadgeel et al. | March 9, 2020
RAPID COMMUNICATIONS
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Warner et al. | February 13, 2020
SPONSORED CONTENT
Sponsored by AstraZeneca
PARP Inhibitors: Changing the Treatment Paradigm in Ovarian Cancer

WHAT'S POPULAR
Last 60 Days
-
Katsuya et al.
-
Key et al.
-
Gadgeel et al.
-
Brahmer et al.
-
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 BlockadeBetof Warner et al.
(Past 365 Days)
-
Ferrell et al.
-
Gilligan et al.
-
Dusetzina et al.
-
Schnipper et al.
-
Schnipper et al.
